AnGes MG Announces Results of Phase I Clinical Trial of HGF Gene Medicine.
In the trials, which covered nine serious cases, the company sought the availability of HGF gene medicine in the treatment of ischemic heart disease. The company says that no significant problem was confirmed in terms of initial safety up until three months after administration.
Currently, AnGes MG is proceeding research in the fields of peripheral vascular disease and ischemic heart disease. The company grants Daiichi Pharmaceutical rights to distribute the medicine in Japan, the US and Europe.
Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||May 11, 2006|
|Previous Article:||Eisai, Nitto Denko to Co-develop Transdermal Formulation of Alzheimer's Disease Agent ARICEPT.|
|Next Article:||Roche Diagnostics to Make Its DNA Chip Available in Japan.|